Celularity Inc.
CELUNASDAQHealthcare● Active
$0.81
$-0.06(-6.92%)
Market Cap$19528914
P/E Ratio—
52W High$4.35
52W Low$0.71
Celularity Inc. (CELU) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CELU · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.59
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
🔥 5-Quarter EPS Beat Streak
CELU reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | May 8, 2026 | — | -$0.59 | — | — | — | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | -$1.50 | -$0.95 | +36.7% | $0.00B | $0.00B | +0.0% |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$1.50 | -$0.88 | +41.3% | $0.01B | — | — |
| — Q3 FY2025 | Aug 29, 2025 | — | -$0.84 | — | $0.01B | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$1.50 | -$0.59 | +60.7% | $0.02B | $0.01B | +248.7% |
| ▲ Q4 FY2024 | Dec 6, 2024 | -$1.40 | -$0.73 | +47.9% | $0.01B | $0.01B | +75.4% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$1.40 | -$0.30 | +78.6% | $0.01B | $0.00B | +175.3% |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026
EPS Actual
-$0.59
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
-$0.95
EPS Est.
-$1.50
EPS Surpr.
+36.7%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.88
EPS Est.
-$1.50
EPS Surpr.
+41.3%
Revenue
$0.01B
Q3 FY2025
Aug 29, 2025
EPS Actual
-$0.84
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.59
EPS Est.
-$1.50
EPS Surpr.
+60.7%
Revenue
$0.02B
Q4 FY2024
Dec 6, 2024Beat
EPS Actual
-$0.73
EPS Est.
-$1.40
EPS Surpr.
+47.9%
Revenue
$0.01B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.30
EPS Est.
-$1.40
EPS Surpr.
+78.6%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-1.50 | $-1.50 | $-1.50 | 1 |
| Q3 FY2025 | $-1.50 | $-1.50 | $-1.50 | 1 |
| Q4 FY2024 | $-1.50 | $-1.50 | $-1.50 | 1 |
| Q3 FY2024 | $-1.40 | $-1.40 | $-1.40 | 1 |
| Q2 FY2024 | $-1.40 | $-1.40 | $-1.40 | 1 |
| Q1 FY2024 | $-1.40 | $-1.40 | $-1.40 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 8, 2026 | — | $0.91 | $0.88 | -3.04% |
| ▲ Q2 FY2026 | Apr 30, 2026 | +36.7% | $0.96 | $0.93 | -2.68% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +41.3% | $1.59 | $1.55 | -2.52% |
| — Q3 FY2025 | Aug 29, 2025 | — | $3.85 | $3.94 | +2.34% |
| ▲ Q2 FY2025 | May 8, 2025 | +60.7% | $1.67 | $1.66 | -0.60% |
| ▲ Q4 FY2024 | Dec 6, 2024 | +47.9% | $2.32 | $2.36 | +1.72% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +78.6% | $1.45 | $3.09 | +113.10% |
| — Q3 FY2024 | Sep 27, 2024 | — | $3.00 | $2.99 | -0.33% |
Q2 FY2026-3.04%
Report Date
May 8, 2026
EPS Beat/Miss
—
Price Before
$0.91
Price After
$0.88
Q2 FY2026-2.68%
Report Date
Apr 30, 2026
EPS Beat/Miss
+36.7%
Price Before
$0.96
Price After
$0.93
Q4 FY2025-2.52%
Report Date
Nov 14, 2025
EPS Beat/Miss
+41.3%
Price Before
$1.59
Price After
$1.55
Q3 FY2025+2.34%
Report Date
Aug 29, 2025
EPS Beat/Miss
—
Price Before
$3.85
Price After
$3.94
Q2 FY2025-0.60%
Report Date
May 8, 2025
EPS Beat/Miss
+60.7%
Price Before
$1.67
Price After
$1.66
Q4 FY2024+1.72%
Report Date
Dec 6, 2024
EPS Beat/Miss
+47.9%
Price Before
$2.32
Price After
$2.36
Q4 FY2024+113.10%
Report Date
Nov 7, 2024
EPS Beat/Miss
+78.6%
Price Before
$1.45
Price After
$3.09
Q3 FY2024-0.33%
Report Date
Sep 27, 2024
EPS Beat/Miss
—
Price Before
$3.00
Price After
$2.99
Avg Beat Reaction+21.80%
Beat Rate5 / 8 quarters
Largest Move+113.10% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CELU ends December
Celularity Inc. (CELU) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.59 (in line with the analyst consensus of —). CELU has beaten EPS estimates for 5 consecutive quarters. The next CELU earnings date is expected around September 1, 2026.
Each quarter, investors track CELU earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CELU revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CELU's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CELU earnings · 4 questionsCelularity Inc.'s next earnings report is expected around September 1, 2026. CELU typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CELU historically reports after market close (AMC).
CELU earnings datewhen is CELU earningsCELU next earnings datewhen does CELU report earningsCELU earnings calendar
▸ Source: FMP · Celularity Inc. SEC filings · US GAAP · Celularity Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026